Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

179
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
179
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

142
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
142
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

242
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
242
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

228
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
228
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.9K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

325
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
325

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What Are the Potential Therapeutic Benefits of Targeting Blood-Borne Lipoproteins in the Treatment of Alzheimer's Disease?

Cells·2026
Same author

Electrical Control and High-Bias Enhancement of Magnetoresistance in van der Waals Antiferromagnetic Spin-Filter Tunnel Field-Effect Transistor.

ACS nano·2026
Same author

Assessing <i>Corynebacterium glutamicum</i> as a surrogate of <i>Mycobacterium tuberculosis</i> for DNA gyrase inhibitor design.

bioRxiv : the preprint server for biology·2026
Same author

The COPI coatomer influences LDL receptor activity, hepatic lipid storage, and apoB secretion.

bioRxiv : the preprint server for biology·2026
Same author

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.

Pathogens & immunity·2026
Same author

TBSure: an ESGMYC survey of pediatric TB management practices in high-income countries.

Frontiers in public health·2026

Related Experiment Video

Updated: Jun 29, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K

[Advances in antibiotic therapy for tuberculosis].

Thomas Maitre1, Lorenzo Guglielmetti2, Jérôme Robert2

  • 1AP-HP. Sorbonne Université, Centre national de référence des mycobactéries et de la résistance des mycobactéries aux antituberculeux, Paris, France. Département de pneumologie, centre de référence des maladies rares pulmonaires, AP-HP. Sorbonne Université, Paris, France.

La Revue Du Praticien
|March 29, 2024
PubMed
Summary

New antibiotic therapies are shortening treatment for drug-susceptible and multidrug-resistant tuberculosis. Personalized treatment plans based on disease severity offer further advancements in tuberculosis care.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Related Experiment Videos

Last Updated: Jun 29, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Context:

  • Tuberculosis (TB) treatment traditionally involves long durations.
  • Drug-resistant strains pose significant global health challenges.
  • Advancements in antibiotic development are crucial for effective TB control.

Purpose:

  • To summarize recent advancements in antibiotic therapy for tuberculosis.
  • To highlight new treatment regimens for both drug-susceptible and multidrug-resistant TB.
  • To discuss personalized treatment strategies based on disease severity.

Summary:

  • A novel regimen using rifapentine and moxifloxacin reduces treatment duration for drug-susceptible TB from 6 to 4 months.
  • Combinations of new drugs like bedaquiline, linezolid, delamanid/pretomanid, and moxifloxacin show potential to shorten multidrug-resistant TB treatment from 20 to 6 months.
  • Treatment duration can be personalized based on anatomical involvement and bacterial load.

Impact:

  • These advancements promise shorter, more effective, and personalized tuberculosis treatment regimens.
  • Reduced treatment duration can improve patient adherence and reduce the burden of disease.
  • New therapeutic strategies are vital for combating the global threat of tuberculosis.